Dynamic Changes of Inhibitory Killer-Immunoglobulin-Like Receptors on NK Cells after Allogeneic Hematopoietic Stem Cell Transplantation: An Initial Study.

HSCT KIRs NK cells

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
29 Oct 2020
Historique:
received: 29 09 2020
revised: 27 10 2020
accepted: 28 10 2020
entrez: 3 11 2020
pubmed: 4 11 2020
medline: 4 11 2020
Statut: epublish

Résumé

Killer-immunoglobulin-like receptors (KIRs) are critical natural killer (NK) cell regulators. The expression of KIRs is a dynamic process influenced by many factors. Their ligands-HLA(Human Leukocyte Antigen) class I molecules-are expressed on all nucleated cells that keep NK cells under control. In hematopoietic stem cell transplantation (HSCT), NK cells play an essential role in relapse protection. In the presented pilot study, we characterized the dynamic expression of inhibitory KIRS (iKIRs), which protect cells against untoward lysis, in donors and patients during the first three months after HSCT using flow cytometry. The expression of all iKIRs was highly variable and sometimes correlated with patients' clinical presentation and therapy regiment. Cyclophosphamide (Cy) in the graft-versus-host disease (GvHD) prevention protocol downregulated KIR2DL1 to just 25% of the original donor value, and the FEAM (Fludarabine + Etoposid + Ara-C + Melphalan) conditioning protocol reduced KIR2DL3. In lymphoid neoplasms, there was a slightly increased KIR2DL3 expression compared to myeloid malignancies. Additionally, we showed that the ex vivo activation of NK cells did not alter the level of iKIRs. Our study shows the influence of pre- and post-transplantation protocols on iKIR expression on the surface of NK cells and the importance of monitoring their cell surface.

Identifiants

pubmed: 33138211
pii: jcm9113502
doi: 10.3390/jcm9113502
pmc: PMC7692795
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : NV18-03-00277

Références

Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Front Immunol. 2019 May 28;10:1179
pubmed: 31231370
Front Immunol. 2020 Mar 12;11:429
pubmed: 32226430
Bone Marrow Transplant. 2017 Oct;52(10):1428-1435
pubmed: 28650455
Immunogenetics. 2020 Apr;72(3):135-141
pubmed: 31900503
Front Immunol. 2012 Sep 17;3:289
pubmed: 23060877
Front Immunol. 2018 Jul 26;9:1672
pubmed: 30093901
Eur J Immunol. 2013 Feb;43(2):480-7
pubmed: 23161492
Curr Opin Immunol. 2018 Feb;50:102-111
pubmed: 29413815
Front Immunol. 2016 Apr 15;7:144
pubmed: 27148263
Front Immunol. 2015 Feb 02;6:31
pubmed: 25699048
Immunol Lett. 2013 Sep-Oct;155(1-2):11-3
pubmed: 24076315
Front Immunol. 2014 Aug 25;5:405
pubmed: 25202311
Front Immunol. 2017 May 19;8:547
pubmed: 28579987
Curr Opin Immunol. 2018 Apr;51:146-153
pubmed: 29605760
J Immunol. 2002 Mar 1;168(5):2307-15
pubmed: 11859120
PLoS One. 2017 Jan 20;12(1):e0169512
pubmed: 28107369
PLoS One. 2014 Jan 22;9(1):e86619
pubmed: 24466173
Eur J Immunol. 2004 Nov;34(11):3028-38
pubmed: 15368269
Tissue Antigens. 2013 Dec;82(6):363-73
pubmed: 24498992
Genes (Basel). 2019 Aug 09;10(8):
pubmed: 31405037
Front Immunol. 2018 Dec 04;9:2843
pubmed: 30564239
Front Immunol. 2013 Feb 21;4:36
pubmed: 23440333
Eur J Immunol. 2018 Feb;48(2):355-365
pubmed: 29105756
Int J Mol Sci. 2019 Jul 15;20(14):
pubmed: 31311121
Science. 2002 Mar 15;295(5562):2029-31
pubmed: 11896262
Hematology Am Soc Hematol Educ Program. 2004;:337-53
pubmed: 15561691
Oncotarget. 2018 Apr 3;9(25):17675-17688
pubmed: 29707140
PLoS One. 2012;7(11):e47491
pubmed: 23139747
Front Immunol. 2019 May 29;10:1158
pubmed: 31191533
Immunology. 2010 Jan;129(1):8-19
pubmed: 20028428
Bone Marrow Transplant. 2018 Sep;53(9):1170-1179
pubmed: 29549293
Bone Marrow Transplant. 2010 Jun;45(6):1022-30
pubmed: 20118994
Front Immunol. 2012 Nov 22;3:336
pubmed: 23189078
Blood. 2013 Jun 6;121(23):4703-7
pubmed: 23637128
Immunol Rev. 2008 Aug;224:58-69
pubmed: 18759920
Leukemia. 2006 Aug;20(8):1437-8
pubmed: 16761016
Genes Immun. 2014 Dec;15(8):562-8
pubmed: 25253288

Auteurs

Tereza Dekojová (T)

Department of Haematology and Oncology, University Hospital Pilsen, 304 60 Pilsen, Czech Republic.
Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, 301 66 Pilsen, Czech Republic.

Lucie Houdová (L)

NTIS, Faculty of Applied Science, University of West Bohemia, 301 00 Pilsen, Czech Republic.

Jiří Fatka (J)

NTIS, Faculty of Applied Science, University of West Bohemia, 301 00 Pilsen, Czech Republic.

Pavel Pitule (P)

Department of Haematology and Oncology, University Hospital Pilsen, 304 60 Pilsen, Czech Republic.
Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic.

Pavel Ostašov (P)

Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic.

Valentina S Caputo (VS)

Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London W12 0NN, UK.

Hana Gmucová (H)

Department of Haematology and Oncology, University Hospital Pilsen, 304 60 Pilsen, Czech Republic.

Daniel Lysák (D)

Department of Haematology and Oncology, University Hospital Pilsen, 304 60 Pilsen, Czech Republic.

Pavel Jindra (P)

Department of Haematology and Oncology, University Hospital Pilsen, 304 60 Pilsen, Czech Republic.

Monika Holubová (M)

Department of Haematology and Oncology, University Hospital Pilsen, 304 60 Pilsen, Czech Republic.
Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic.

Classifications MeSH